NCT Number: NCT00163475
Efficacy and Safety of Roflumilast Taken in the Morning or Evening in Patients With Stable Asthma (12 to 70 y) (BY217/M2-015)
Bronchial asthma is among the world's most prevalent diseases. Roflumilast is a novel, orally active, selective enzyme inhibitor (phosphodiesterase 4 inhibitor), which has shown effectiveness in the treatment of asthma.
The aim of the study is to compare the effect of roflumilast on lung function, symptoms, and use of rescue medication in patients with stable asthma. Roflumilast will be administered orally either in the morning or in the evening at one dose level. The study duration consists of a baseline period (1 to 2 weeks) and a treatment period (6 weeks). The study will provide further data on safety, tolerability, and effectiveness of roflumilast.
Looking for future studies?
Notify MeKey information
Conditions
Age range
12 year–70 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
ALTANA Pharma, Cities in Australia, Australia
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Main Inclusion Criteria:
- Written informed consent
- Diagnosis of persistent bronchial asthma (with reference to the Global Initiative for Asthma Guidelines 2002)
- Baseline FEV1 50 - 85% in patients either untreated or receiving e.g. short-acting bronchodilators, DSCG, nedocromil, anticholinergics, long-acting bronchodilators, theophylline/aminophylline, lipoxygenase inhibitors, leukotriene antagonists, alone or in combination
- Baseline FEV1 60 - 90% in patients receiving not more than 500 mcg BDP-CFC (or equivalent) and/or in combination with any other asthma medication mentioned above
- No change in the asthma treatment 4 weeks prior to baseline period
- Patients who, with the exception of asthma, are in good health
Main Exclusion Criteria:
- Poorly controlled asthma: requirement of a course of oral and/or parenteral glucocorticosteroids 4 weeks prior to the baseline, or admission to hospital for asthma (including treatment in an emergency room) 4 weeks prior to the baseline period, or asthma exacerbation in the last 4 weeks prior to baseline period
- Patient using regularly >8 puffs/day rescue medication prior to baseline
- History of lower airway infection in the last 4 weeks prior to baseline period
- Diagnosis of chronic obstructive pulmonary disease and/or other relevant lung diseases
- Heavy smoker: currently: >20 cigarettes/day and/or >10 pack years, ex-smoker: with a smoking history of ≥10 pack years
- Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation
- Liver insufficiency (Child Pugh A or worse)
- Active hepatitis
- Known infection with HIV
- Diagnosis or history of cancer (other than basal cell carcinoma) or recurrence within 5 years prior to study start
- Alcohol and/or drug abuse
- Suspected hypersensitivity and/or contraindication to any ingredients of the study medication (roflumilast) or rescue medication
- Pregnancy or patient of childbearing potential who is not using reliable method of contraception
- Patients not able to follow study procedures, e.g. due to language problems, psychological disorders
- Suspected inability or unwillingness to comply with the study procedures
Treatment and study plan
Primary outcomes
-
mean change from randomization to endpoint in forced expiratory volume in one second.
Secondary outcomes
-
forced expiratory vital capacity
-
peak expiratory flow
-
morning and evening peak expiratory flow (patient's diary)
-
symptom score and use of rescue medication (patient's diary)
-
Asthma Control Questionnaire (ACQ)
-
proportion of symptom-free days / rescue medication-free days asthma exacerbations.
Sponsors and collaborators
Lead sponsor
AstraZeneca
Industry
Registry information
Official study title
The MOVE-study: Morning Versus Evening Administration of 500 mcg Roflumilast Once Daily for 6 Weeks in Patients With Asthma
Important dates
- Study start
- 2004
- Primary completion
- 2005
- Study completion
- 2005
- First posted
- Sep 14, 2005
- Registry last updated
- Oct 25, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Community-Based Swimming and Inspiratory Muscle Training Intervention to Promote Physical Activity and Asthma Control in Children With Mild Asthma
NCT07394127
Asthma, Asthma Chronic
Gümüşhane, Trabzon, Ordu, Giresun, Rize, Artvin, Gümüşhane, Turkey (Türkiye)
View Trial DetailsThe COX-2 Gene and the Immune System
NCT01678222
Allergic Inflammation, Asthma
Research Triangle Park, North Carolina, United States
View Trial DetailsNew Approaches for Empowering Studies of Asthma in Populations of African Descent
NCT03937804
Asthma, Bronchial Diseases
Bethesda, Maryland, United States
View Trial DetailsA Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
NCT03927820
Asthma, Bronchial Diseases
Nashville, Tennessee, United States
View Trial Details